Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HUYGENS: Evolocumab for Plaque Stability in NSTE-ACS
NCT03570697Phase 3Completed
- Sponsor
- Amgen
- Start
- Nov 2018
- Primary completion
- Dec 2020
- Modality
- Monoclonal Antibodies
- Countries
- 7
01
Overview
A Phase 3 trial of evolocumab in non-ST elevation acute coronary syndrome (NSTE-ACS), sponsored by Amgen. Started Nov 2018; status: completed.
02
Drugs
evolocumab
03
Conditions
non-ST elevation acute coronary syndrome (NSTE-ACS)
Beyond the preview
Go deeper on NCT03570697.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03570697.